| Improved survival with vemurafenib in melanoma with BRAF V600E mutation PB Chapman, A Hauschild, C Robert, JB Haanen, P Ascierto, J Larkin, ... New England Journal of Medicine 364 (26), 2507-2516, 2011 | 9126 | 2011 |
| Final version of 2009 AJCC melanoma staging and classification CM Balch, JE Gershenwald, S Soong, JF Thompson, MB Atkins, DR Byrd, ... Journal of clinical oncology 27 (36), 6199-6206, 2009 | 5562 | 2009 |
| Inhibition of mutated, activated BRAF in metastatic melanoma KT Flaherty, I Puzanov, KB Kim, A Ribas, GA McArthur, JA Sosman, ... New England Journal of Medicine 363 (9), 809-819, 2010 | 4285 | 2010 |
| Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq I Tirosh, B Izar, SM Prakadan, MH Wadsworth, D Treacy, JJ Trombetta, ... Science 352 (6282), 189-196, 2016 | 3963 | 2016 |
| Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations KT Flaherty, JR Infante, A Daud, R Gonzalez, RF Kefford, J Sosman, ... New England Journal of Medicine 367 (18), 1694-1703, 2012 | 3122 | 2012 |
| Improved overall survival in melanoma with combined dabrafenib and trametinib C Robert, B Karaszewska, J Schachter, P Rutkowski, A Mackiewicz, ... New England Journal of Medicine 372 (1), 30-39, 2015 | 2923 | 2015 |
| Genomic classification of cutaneous melanoma R Akbani, KC Akdemir, B áArman Aksoy, M Albert, A Ally, SB Amin, ... Cell 161 (7), 1681-1696, 2015 | 2711 | 2015 |
| Improved survival with MEK inhibition in BRAF-mutated melanoma KT Flaherty, C Robert, P Hersey, P Nathan, C Garbe, M Milhem, ... New England Journal of Medicine 367 (2), 107-114, 2012 | 2599 | 2012 |
| Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib JA Sosman, KB Kim, L Schuchter, R Gonzalez, AC Pavlick, JS Weber, ... New England Journal of Medicine 366 (8), 707-714, 2012 | 2592 | 2012 |
| Melanoma staging: evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual JE Gershenwald, RA Scolyer, KR Hess, VK Sondak, GV Long, MI Ross, ... CA: a cancer journal for clinicians 67 (6), 472-492, 2017 | 2264* | 2017 |
| Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma G Bollag, P Hirth, J Tsai, J Zhang, PN Ibrahim, H Cho, W Spevak, C Zhang, ... Nature 467 (7315), 596-599, 2010 | 2037 | 2010 |
| Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, ... New England Journal of Medicine 371 (20), 1877-1888, 2014 | 2009 | 2014 |
| Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion R Straussman, T Morikawa, K Shee, M Barzily-Rokni, ZR Qian, J Du, ... Nature 487 (7408), 500-504, 2012 | 1960 | 2012 |
| COT drives resistance to RAF inhibition through MAP kinase pathway reactivation CM Johannessen, JS Boehm, SY Kim, SR Thomas, L Wardwell, ... Nature 468 (7326), 968-972, 2010 | 1722 | 2010 |
| RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E) PI Poulikakos, Y Persaud, M Janakiraman, X Kong, C Ng, G Moriceau, ... Nature 480 (7377), 387-390, 2011 | 1645 | 2011 |
| Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F De Braud, J Larkin, ... The Lancet 386 (9992), 444-451, 2015 | 1551 | 2015 |
| Defining T cell states associated with response to checkpoint immunotherapy in melanoma M Sade-Feldman, K Yizhak, SL Bjorgaard, JP Ray, CG de Boer, ... Cell 175 (4), 998-1013. e20, 2018 | 1428 | 2018 |
| Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine LT Geller, M Barzily-Rokni, T Danino, OH Jonas, N Shental, D Nejman, ... Science 357 (6356), 1156-1160, 2017 | 1356 | 2017 |
| Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma MJ Ratain, TIM Eisen, WM Stadler, KT Flaherty, SB Kaye, GL Rosner, ... Journal of Clinical Oncology 24 (16), 2505-2512, 2006 | 1311 | 2006 |
| Mechanisms of resistance to immune checkpoint inhibitors RW Jenkins, DA Barbie, KT Flaherty British journal of cancer 118 (1), 9-16, 2018 | 1243 | 2018 |
